The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China
<p>Abstract</p> <p>Background</p> <p>Health related quality of life (HRQOL) has increasingly emphasized on cancer patients. The psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-04-01
|
Series: | BMC Medical Research Methodology |
Online Access: | http://www.biomedcentral.com/1471-2288/11/56 |
id |
doaj-54df7ff9b135431b8744b1d9da91a76b |
---|---|
record_format |
Article |
spelling |
doaj-54df7ff9b135431b8744b1d9da91a76b2020-11-25T01:05:29ZengBMCBMC Medical Research Methodology1471-22882011-04-011115610.1186/1471-2288-11-56The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in ChinaZhang Hong-yingZhang Yong-qinWang RuiLin WeiZhang Yong-qiangZhang XiangLiu Bo-linCheng Jin-xiangXie LiHuo Jun-li<p>Abstract</p> <p>Background</p> <p>Health related quality of life (HRQOL) has increasingly emphasized on cancer patients. The psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30, version 3.0) in brain tumor patients wasn't proven, and there was no baseline HRQOL in brain tumor patients prior to surgery.</p> <p>Methods</p> <p>The questionnaire EORTC QLQ-C30 (version 3.0) was administered at three time points: T1, the first or the second day that patients were hospitalized after the brain tumor suspected or diagnosed by MRI or CT; T2, 1 to 2 days after T1, (T1 and T2 were both before surgery); T3, the day before discharge. Clinical variables included disease histologic types, cognitive function, and Karnofsky Performance Status.</p> <p>Results</p> <p>Cronbach's alpha coefficients for multi-item scales were greater than .70 and multitrait scaling analysis showed that most of the item-scale correlation coefficients met the standards of convergent and discriminant validity, except for the cognitive functioning scale. All scales and items exhibited construct validity. Score changes over peri-operation were observed in physical and role functioning scales. Compared with mixed cancer patients assessed after surgery but before adjuvant treatment, brain tumor patients assessed pre-surgery presented better function and fewer symptoms.</p> <p>Conclusions</p> <p>The standard Chinese version of the EORTC QLQ-C30 was overall a valid instrument to assess HRQOL in brain tumor patients in China. The baseline HRQOL in brain tumor patients pre-surgery was better than that in mixed cancer patients post-surgery. Future study should modify cognitive functioning scale and examine test-retest reliability and response validity.</p> http://www.biomedcentral.com/1471-2288/11/56 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zhang Hong-ying Zhang Yong-qin Wang Rui Lin Wei Zhang Yong-qiang Zhang Xiang Liu Bo-lin Cheng Jin-xiang Xie Li Huo Jun-li |
spellingShingle |
Zhang Hong-ying Zhang Yong-qin Wang Rui Lin Wei Zhang Yong-qiang Zhang Xiang Liu Bo-lin Cheng Jin-xiang Xie Li Huo Jun-li The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China BMC Medical Research Methodology |
author_facet |
Zhang Hong-ying Zhang Yong-qin Wang Rui Lin Wei Zhang Yong-qiang Zhang Xiang Liu Bo-lin Cheng Jin-xiang Xie Li Huo Jun-li |
author_sort |
Zhang Hong-ying |
title |
The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China |
title_short |
The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China |
title_full |
The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China |
title_fullStr |
The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China |
title_full_unstemmed |
The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China |
title_sort |
validation of the standard chinese version of the european organization for research and treatment of cancer quality of life core questionnaire 30 (eortc qlq-c30) in pre-operative patients with brain tumor in china |
publisher |
BMC |
series |
BMC Medical Research Methodology |
issn |
1471-2288 |
publishDate |
2011-04-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Health related quality of life (HRQOL) has increasingly emphasized on cancer patients. The psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30, version 3.0) in brain tumor patients wasn't proven, and there was no baseline HRQOL in brain tumor patients prior to surgery.</p> <p>Methods</p> <p>The questionnaire EORTC QLQ-C30 (version 3.0) was administered at three time points: T1, the first or the second day that patients were hospitalized after the brain tumor suspected or diagnosed by MRI or CT; T2, 1 to 2 days after T1, (T1 and T2 were both before surgery); T3, the day before discharge. Clinical variables included disease histologic types, cognitive function, and Karnofsky Performance Status.</p> <p>Results</p> <p>Cronbach's alpha coefficients for multi-item scales were greater than .70 and multitrait scaling analysis showed that most of the item-scale correlation coefficients met the standards of convergent and discriminant validity, except for the cognitive functioning scale. All scales and items exhibited construct validity. Score changes over peri-operation were observed in physical and role functioning scales. Compared with mixed cancer patients assessed after surgery but before adjuvant treatment, brain tumor patients assessed pre-surgery presented better function and fewer symptoms.</p> <p>Conclusions</p> <p>The standard Chinese version of the EORTC QLQ-C30 was overall a valid instrument to assess HRQOL in brain tumor patients in China. The baseline HRQOL in brain tumor patients pre-surgery was better than that in mixed cancer patients post-surgery. Future study should modify cognitive functioning scale and examine test-retest reliability and response validity.</p> |
url |
http://www.biomedcentral.com/1471-2288/11/56 |
work_keys_str_mv |
AT zhanghongying thevalidationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT zhangyongqin thevalidationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT wangrui thevalidationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT linwei thevalidationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT zhangyongqiang thevalidationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT zhangxiang thevalidationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT liubolin thevalidationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT chengjinxiang thevalidationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT xieli thevalidationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT huojunli thevalidationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT zhanghongying validationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT zhangyongqin validationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT wangrui validationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT linwei validationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT zhangyongqiang validationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT zhangxiang validationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT liubolin validationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT chengjinxiang validationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT xieli validationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina AT huojunli validationofthestandardchineseversionoftheeuropeanorganizationforresearchandtreatmentofcancerqualityoflifecorequestionnaire30eortcqlqc30inpreoperativepatientswithbraintumorinchina |
_version_ |
1725194343059292160 |